Figure above illustrates a COVID-19 vaccine particle consisting of a liposome and recombinant viral protein antigens from SARS-CoV-2. We have developed different vaccine development processes and shown promising results in animal studies. Our COVID-19 vaccine is currently in the preclinical stage.
Preliminary results have shown that Engimata’s freeze-dried COVID-19 vaccine candidate is stable at 25C at least for 3 months and can be distributed without the need for a cold or ultra-cold supply chain. Engimata’s lyophilized COVID-19 vaccine can be easily reconstituted prior to injection.